Loading...
•
Sep 30, 2021
Fate Therapeutics Q3 2021 Earnings Report
Fate Therapeutics reported third quarter 2021 financial results and highlighted operational progress.
Key Takeaways
Fate Therapeutics reported a revenue of $14.2 million for the third quarter of 2021, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $803.6 million as of September 30, 2021. The company is advancing its iPSC-derived NK cell product candidates.
Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma
FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 71% ORR and 50% CR; Differentiated Safety Profile with Two Low-Grade Events of CRS and No Events of ICANS or GVHD
FT516 Interim Phase 1 Data of 11 Patients in Multi-Dose, Multi-Cycle Escalation Cohorts 2 and 3 for R/R Lymphoma Showed 73% ORR and 55% CR; 63% of Responders Remained in Ongoing Response at Median Time of 5.2 Months; Enrollment in Multiple Disease-specific Expansion Cohorts Initiated
FT596 Oral and FT516 Poster Presentations to Highlight Updated Phase 1 Data for R/R Lymphoma at ASH on Monday, December 13; Eight Abstracts Accepted for Presentation
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com